Freeze-dried Rotavirus Vaccine Shows Promise

• Autores: M. J. Friedrich
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 317, Nº. 19, 2017, págs. 1941-1941
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Three doses of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV) protected healthy infants in Niger from severe rotavirus gastroenteritis, reported a team of international investigators in the New England Journal of Medicine.

    Rotavirus is a leading cause of diarrhea-associated hospitalization and death in children younger than 5 years around the world, with the highest death rate from this virus occurring in sub-Saharan Africa. Currently there are 2 licensed vaccines in use against rotavirus, but both require refrigeration. The BRV-PV vaccine, which was designed specifically for use in remote areas with limited electricity or health clinics, is freeze-dried, does not require refrigeration, and is thermostable for 2 years at 37°C and for 6 months at 40°C.

    First Page Preview